JP2006104221A5 - - Google Patents

Download PDF

Info

Publication number
JP2006104221A5
JP2006104221A5 JP2006002227A JP2006002227A JP2006104221A5 JP 2006104221 A5 JP2006104221 A5 JP 2006104221A5 JP 2006002227 A JP2006002227 A JP 2006002227A JP 2006002227 A JP2006002227 A JP 2006002227A JP 2006104221 A5 JP2006104221 A5 JP 2006104221A5
Authority
JP
Japan
Prior art keywords
botulinum toxin
composition
bloated
preparing
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006002227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006104221A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2006104221A publication Critical patent/JP2006104221A/ja
Publication of JP2006104221A5 publication Critical patent/JP2006104221A5/ja
Pending legal-status Critical Current

Links

JP2006002227A 1997-07-15 2006-01-10 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法 Pending JP2006104221A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5258097P 1997-07-15 1997-07-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004367501A Division JP2005089479A (ja) 1997-07-15 2004-12-20 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009264712A Division JP5005753B2 (ja) 1997-07-15 2009-11-20 患者の膀胱圧の上昇を低減するための、又は患者の膀胱容量を増大させるための製薬組成物の調製においてボツリヌス毒素を使用する方法

Publications (2)

Publication Number Publication Date
JP2006104221A JP2006104221A (ja) 2006-04-20
JP2006104221A5 true JP2006104221A5 (enExample) 2008-08-28

Family

ID=21978526

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2000502781A Expired - Lifetime JP3692033B2 (ja) 1997-07-15 1998-07-15 泌尿器疾患及び関連疾患の治療のための神経毒治療法の使用
JP2004367501A Pending JP2005089479A (ja) 1997-07-15 2004-12-20 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法
JP2004367500A Expired - Lifetime JP3955061B2 (ja) 1997-07-15 2004-12-20 泌尿器疾患を治療するための治療剤
JP2005331664A Expired - Lifetime JP4053559B2 (ja) 1997-07-15 2005-11-16 過活動膀胱を治療するための治療剤
JP2006002227A Pending JP2006104221A (ja) 1997-07-15 2006-01-10 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法
JP2007002407A Expired - Lifetime JP4696082B2 (ja) 1997-07-15 2007-01-10 脊髄損傷により二次的に起こる尿失禁の症状を治療する治療剤
JP2007002406A Expired - Lifetime JP4672676B2 (ja) 1997-07-15 2007-01-10 会陰部疼痛、睾丸痛又はペニス軸の疼痛を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法
JP2008107792A Expired - Lifetime JP4815468B2 (ja) 1997-07-15 2008-04-17 夜間睡眠時の頻繁な尿意に苦しむ患者を治療するための治療剤
JP2009264712A Expired - Lifetime JP5005753B2 (ja) 1997-07-15 2009-11-20 患者の膀胱圧の上昇を低減するための、又は患者の膀胱容量を増大させるための製薬組成物の調製においてボツリヌス毒素を使用する方法

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2000502781A Expired - Lifetime JP3692033B2 (ja) 1997-07-15 1998-07-15 泌尿器疾患及び関連疾患の治療のための神経毒治療法の使用
JP2004367501A Pending JP2005089479A (ja) 1997-07-15 2004-12-20 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法
JP2004367500A Expired - Lifetime JP3955061B2 (ja) 1997-07-15 2004-12-20 泌尿器疾患を治療するための治療剤
JP2005331664A Expired - Lifetime JP4053559B2 (ja) 1997-07-15 2005-11-16 過活動膀胱を治療するための治療剤

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2007002407A Expired - Lifetime JP4696082B2 (ja) 1997-07-15 2007-01-10 脊髄損傷により二次的に起こる尿失禁の症状を治療する治療剤
JP2007002406A Expired - Lifetime JP4672676B2 (ja) 1997-07-15 2007-01-10 会陰部疼痛、睾丸痛又はペニス軸の疼痛を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法
JP2008107792A Expired - Lifetime JP4815468B2 (ja) 1997-07-15 2008-04-17 夜間睡眠時の頻繁な尿意に苦しむ患者を治療するための治療剤
JP2009264712A Expired - Lifetime JP5005753B2 (ja) 1997-07-15 2009-11-20 患者の膀胱圧の上昇を低減するための、又は患者の膀胱容量を増大させるための製薬組成物の調製においてボツリヌス毒素を使用する方法

Country Status (15)

Country Link
US (5) US6365164B1 (enExample)
EP (8) EP1502601B2 (enExample)
JP (9) JP3692033B2 (enExample)
KR (1) KR100544060B1 (enExample)
CN (5) CN1803189B (enExample)
AT (5) ATE339220T1 (enExample)
AU (2) AU743085B2 (enExample)
CA (5) CA2296720C (enExample)
CY (3) CY1105816T1 (enExample)
DE (4) DE69833059T3 (enExample)
DK (6) DK1949909T3 (enExample)
ES (6) ES2385130T3 (enExample)
LU (2) LU92055I2 (enExample)
PT (5) PT1011695E (enExample)
WO (1) WO1999003483A1 (enExample)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
ATE339220T1 (de) 1997-07-15 2006-10-15 Univ Colorado Verwendung einer neurotoxintherapie zur behandlung der harnverhaltung
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US9066943B2 (en) * 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7470431B2 (en) * 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
ES2245524B1 (es) * 1999-04-01 2007-03-16 Heeling Sports Limited Aparato y metodo de talonaje.
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6773711B2 (en) 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
GB0029125D0 (en) * 2000-11-29 2001-01-10 Specialistkliniken I Varberg H Novel treatment
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
JP4174673B2 (ja) * 2001-07-10 2008-11-05 アステラス製薬株式会社 間質性膀胱炎治療用医薬組成物
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
ES2401570T3 (es) 2001-11-15 2013-04-22 Phytotox Limited Composiciones farmacéuticas que contienen 3,4-propinoperhidropurinas y usos de las mismas para bloquear la transmisión neuronal
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
AU2003259246A1 (en) * 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
GB2398636A (en) * 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
CN1874784B (zh) * 2003-03-06 2010-06-09 肉毒素研究同仁股份有限公司 用肉毒杆菌毒素治疗鼻窦炎相关的慢性面部疼痛及头痛
MXPA05009424A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento de chalazion cronico y hordeolum con la toxina botulinica.
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
US20050096629A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transurethral delivery of a denervating agent to the prostate gland
US20050096549A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transperineal delivery of a denervating agent to the prostate gland
US20050096550A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transrectal delivery of a denervating agent to the prostate gland
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
GB0328060D0 (en) * 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2607206C (en) * 2004-05-07 2016-06-14 Phytotox Limited Transdermal administration of phycotoxins
JP5047782B2 (ja) * 2004-05-07 2012-10-10 ファイトトックス リミテッド フィコトキシン及びその使用
US8173797B2 (en) * 2004-07-21 2012-05-08 Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
WO2006013370A1 (en) 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
PL2813239T3 (pl) * 2004-08-04 2017-11-30 Ipsen Biopharm Limited Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową A2
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
KR20070115580A (ko) 2005-03-03 2007-12-06 알러간, 인코포레이티드 클로스트리디움 박테리아를 위한 배지 및 클로스트리디움계독소를 얻기 위한 프로세스
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
EP1896112A4 (en) * 2005-06-07 2011-04-27 A M S Res Corp INJECTION GUIDANCE SYSTEM AND METHOD
US20070038089A1 (en) * 2005-06-29 2007-02-15 Olympus Medical Systems Corp. Transurethral diagnostic method and treatment method using ultrasonic endoscope
CN101384247B (zh) 2005-07-18 2013-05-22 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
WO2007044748A2 (en) * 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CA2631927C (en) 2005-12-01 2015-08-18 University Of Massachusetts Lowell Botulinum nanoemulsions
US20090312696A1 (en) * 2005-12-28 2009-12-17 Copa Vincent G Devices, Systems, and Related Methods for Delivery of Fluid to Tissue
US7770674B2 (en) * 2006-03-14 2010-08-10 Fallbrook Technologies Inc. Wheel chair
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
US20090304747A1 (en) * 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
BRPI0719732A2 (pt) * 2006-12-01 2017-05-16 Anterios Inc nanopartículas de peptídeo e usos para as mesmas
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
JP2010519211A (ja) * 2007-02-15 2010-06-03 アラーガン、インコーポレイテッド 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用
CN103961315A (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
RU2010120016A (ru) 2007-10-23 2011-11-27 Аллерган, Инк. (Us) Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
EP2376104A4 (en) * 2008-12-15 2014-09-10 Protox Therapeutics Inc Method of treating prostatitis with proaeryslyin, modified pore-forming protein
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
US8133491B1 (en) 2009-01-30 2012-03-13 The University Of Toledo Compositions and methods for treatment of hyperplastic disorders
US20120021969A1 (en) 2009-03-06 2012-01-26 Allergan, Inc. Prosthetic implant shell
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US8198229B2 (en) 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
EP2482838A4 (en) 2009-09-30 2013-04-10 Toxcure Inc USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE
WO2012024286A2 (en) 2010-08-18 2012-02-23 Medtronic, Inc. Urgency therapy with neuromodulation and c-afferent nerve desensitization
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012112426A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Arginine vasopressin retargeted clostridial endopeptidases for use in treating benign prostatic hyperplasia
WO2013009625A1 (en) 2011-07-08 2013-01-17 Allergan, Inc. Method for treatment of autonomic nervous system disorders
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
RU2578475C2 (ru) 2011-07-14 2016-03-27 Аллерган, Инк. Способы лечения недержания, связанного с половой активностью
IN2014DN00254A (enExample) 2011-07-20 2015-06-05 Allergan Inc
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
CN104379127A (zh) * 2012-04-08 2015-02-25 席拉蔻公司 制备用于治疗泌尿上皮失调的热可逆凝胶制剂
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CA2973310C (en) * 2015-02-03 2023-03-14 Hoganas Ab (Publ) Powder metal composition for easy machining
MA45492A (fr) 2016-06-23 2019-05-01 Hopitaux Paris Assist Publique Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
EP3639848A3 (en) 2016-09-13 2020-12-16 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
RU2687106C1 (ru) * 2017-12-19 2019-05-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ лечения синдрома гиперактивного мочевого пузыря
LT3660509T (lt) 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti
CN110935009B (zh) * 2019-12-24 2023-07-11 云南南诏药业有限公司 科博肽制剂在制备治疗痔疮药物中的应用
RU2768606C1 (ru) * 2021-04-16 2022-03-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр колопроктологии имени А.Н. Рыжих" Министерства здравоохранения Российской Федерации Способ комбинированного хирургического лечения хронической анальной трещины со спазмом сфинктера методом иссечения трещины в сочетании с инъекцией ботулинического токсина типа А в дозировке 40 ЕД во внутренний анальный сфинктер под ультразвуковой навигацией

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932936A (en) † 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
JPH0642950Y2 (ja) * 1988-10-15 1994-11-09 株式会社マイコー ケース固定装置
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JP4249802B2 (ja) 1993-06-10 2009-04-08 アラーガン、インコーポレイテッド 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
ES2248780T3 (es) 1993-12-28 2008-06-16 Allergan, Inc. Componente neurotoxico de toxinas botulinicas para tratar la distonia cervical.
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US7470431B2 (en) * 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7455845B2 (en) * 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
ATE339220T1 (de) * 1997-07-15 2006-10-15 Univ Colorado Verwendung einer neurotoxintherapie zur behandlung der harnverhaltung
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7449192B2 (en) * 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
JP3655061B2 (ja) * 1997-07-31 2005-06-02 株式会社ニデック 紫外線吸収性基材
JP2000214813A (ja) * 1999-01-22 2000-08-04 Mercury Enterprise:Kk 二輪及び三輪車輌・トラック・四輪車両へ搭載可能な可動式省エネ広告塔
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP2002132198A (ja) * 2000-10-25 2002-05-09 Sukenori Kiuchi 三輪自転車一体型移動式回転広告塔
JP2002306290A (ja) * 2001-04-19 2002-10-22 Takumi:Kk ターンテーブル
JP2007037725A (ja) * 2005-08-02 2007-02-15 Masahiro Matsubara 多機能立方体展示ユニット
JP3121792U (ja) * 2005-10-28 2006-06-01 株式会社イマジンクリエイション ラック付３ｄレンズ使用立体型看板

Similar Documents

Publication Publication Date Title
JP2006104221A5 (enExample)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
NZ592673A (en) Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
GEP20156281B (en) Orally administered corticosteroid compositions
JP2013529665A5 (enExample)
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
UA100403C2 (en) Capsule formulation
JP2009525343A5 (enExample)
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
ATE543489T1 (de) Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür
WO2013183062A3 (en) Palatable formulations of ibuprofen
RU2011103136A (ru) Фармацевтическая композиция на основе тонкоизмельченного прогестерона и ее применения
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
JP2013509395A5 (enExample)
SI2501234T1 (en) Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
BR112012009857A2 (pt) composições farmacêuticas sólidas contendo um inibidor de integrase
BRPI0922806B8 (pt) composição farmacêutica oral compreendendo bendamustina
BR112014009438A2 (pt) composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral
RU2015109566A (ru) НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА
RU2015143475A (ru) Продукт и способ лечения диареи
JP2016505561A5 (enExample)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir